SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

First Tracks Biotherapeutics, Inc. (TRAX) News

Follow First Tracks Biotherapeutics, Inc. (TRAX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 17 public stories across 11 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol TRAX Asset equity Sector Markets 90 days 15 Last 43.525 Updated Nov 03, 2026, 09:40 PM UTC Open live news feed Open TRAX chart & news
M First Tracks Biotherapeutics Reports Third-Quarter Net Loss of $31.4M The company’s diluted loss per share narrowed to $0.88 from $1.50 a year earlier. It also reported progress across its ANB033 and rosnilimab programs. EQUITY | Nov 03, 2026, 09:40 PM UTC M First Tracks Biotherapeutics Reports Third-Quarter 2026 Results and Business Update The company said ANB033 achieved a statistically significant and clinically meaningful protective effect; the available report is truncated before providing further details. EQUITY | Nov 03, 2026, 09:25 PM UTC M First Tracks Biotherapeutics Secures $200 Million Private Placement The company agreed to sell 6,106,870 common shares at $32.75 each to certain third-party investors, for expected gross proceeds of approximately $200 million. The placement is expected to close October 19, 2026. EQUITY | Oct 15, 2026, 08:35 PM UTC M First Tracks Biotherapeutics Reports Positive Phase 1b ANB033 Results The company said ANB033 showed statistically significant protection against gluten-induced intestinal damage and symptoms. EQUITY | Oct 13, 2026, 12:43 PM UTC M TRAX Reports Positive Celiac Study Results; MIRM Meets Phase 3 Endpoint Premarket mover roundup also includes TRMD’s full-year guidance upgrade, talk of advanced sale talks involving CCC, and BMY’s positive interim Phase 3 ACTION-1 results. The source also cites analyst upgrades for CRM, BII EQUITY | Oct 12, 2026, 01:08 PM UTC L First Tracks Biotherapeutics reports positive ANB033 study results The company announced positive top-line results for ANB033 in a gluten-challenge study in celiac disease. EQUITY | Oct 12, 2026, 11:00 AM UTC M First Tracks Shares Rise 15% Ahead of Celiac Trial Data Review First Tracks Biotherapeutics said it would review top-line data from a celiac disease treatment trial on Monday. Shares rose 15% to $36.71 in premarket trading; they were up nearly 68% year to date through Friday's close EQUITY | Oct 12, 2026, 10:13 AM UTC H Stock Market Today: S&P 500, Dow Jones Futures Gain Even as Iran Flags 'Inadequate' US Response to Peace Terms — SMP, QMCO, SVRN in Focus U.S. stock futures were mixed on Monday, as the Dow Jones and S&P 500 indices rose, while the Nasdaq 100 index fell, following Friday’s higher close. Geopolitical tensions flared over the weekend as Iran stepped up attac LIVE | Oct 12, 2026, 09:35 AM UTC L First Tracks Biotherap Initiated at Buy by Canaccord Genuity Ratings actions from Benzinga NEWS | Sep 30, 2026, 11:47 AM UTC L TRAX: Advancing dual-mechanism CD122 therapy in celiac and EoE, with key data and expansion ahead The company, newly formed and well-funded, is advancing a pipeline led by ANB033, a dual-mechanism CD122 antagonist targeting autoimmune diseases, with phase I-B trials in celiac disease and EoE. Data readouts are expect EQUITY | Sep 09, 2026, 03:26 PM UTC L TRAX advances CD122 antibody for celiac and EoE; phase I-B soon TRAX, newly formed from a spinout, is developing a dual-mechanism CD122 antibody for celiac disease and EoE. Phase I-B data are expected soon, with plans to expand into additional indications. EQUITY | Sep 09, 2026, 02:38 PM UTC L TRAX director sells common shares worth $1,758,145 Director Ware J. Anthony reported selling common stock on 2026-09-02 at a weighted average price of $44.7764 per share, for $1,758,145 total. EQUITY | Sep 04, 2026, 08:31 PM UTC L First Tracks Biotherap price target held at $57.00 HC Wainwright & Co. maintained a $57.00-per-share price target for First Tracks Biotherap, according to TradingView News via Benzinga. EQUITY | Sep 03, 2026, 11:54 AM UTC L First Tracks Biotherapeutics to participate in September investor conferences First Tracks Biotherapeutics announced it will participate in September investor conferences. EQUITY | Aug 26, 2026, 08:17 PM UTC L TRAX - First Tracks Biotherapeutics Announces Participation in September Investor Conferences TRAX - First Tracks Biotherapeutics Announces Participation in September Investor Conferences EQUITY | Aug 26, 2026, 08:15 PM UTC L TRAX Announces Q2 2026 Financial Results TRAX announces second quarter 2026 financial results and provides business update EARNINGS | Aug 12, 2026, 08:16 PM UTC L First Tracks Biotherapeutics price target raised by $8 at Barclays, here's why First Tracks Biotherapeutics price target raised by $8 at Barclays, here's why EQUITY | Jul 21, 2026, 10:20 AM UTC